Government Spending Bill Proposes Patent Cap to Boost Biosimilar Competition

In a significant development for the pharmaceutical industry, the newly proposed government spending package aims to keep federal operations running through March, while simultaneously containing a provision that could reshape legal strategies in the biologics sector. The provision sets a cap on the number of patents a biologics manufacturer can assert in efforts to block competition from biosimilars entering the market. This legislative proposal could potentially streamline litigation and impact the dynamics between original biologics manufacturers and biosimilar producers. More details can be explored in the full article on Law360.